The Lymphoma Research Foundation added "A Conversation about Follicular Lymphoma with Dr. Christopher Flowers" about a week ago. Dr. Flowers is director of the lymphoma program at Emory university's cancer center.
It's a brief interview, with some basics about Follicular Lymphoma, and his take on some of the important issues of the field. He was asked, for example, about current research on treatments. He cites a couple of kinase inhibitors -- Ibrutinib and GS-1101 -- that have been making lots of news lately. They certainly seem to be the future of the field, at least as things are defined right now. It will be interesting to see how they get tested in trials in the next few years. In combination with other treatments? As maintenance options? Good, good stuff.
He also mention Bendamustine + Rituxan + Velcade for relapsed Follicular, plus R + R (Revlimid and Rituxin) for maintenance.
More arrows in the quiver.
Dr. Flowers also has suggestions about clinical trials (a great idea) and advice for newly diagnosed patients (get a second opinion and see a specialist who is up on the latest developments -- also great ideas).
So, nothing terribly ground-breaking, but it's always interesting to me to see what gets mentioned by those who are so deeply involved in the field.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment